- CEO
- Yi Jiang Mei
- Full Time Employees
- 4,791
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 99 Waisha Road Taizhou ZH China 318000
- IPO Date
- Sep 23, 2014
- Business
- Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and generic formulations. The company produces a range of core products including steroid APIs such as budesonide, progesterone, dexamethasone, betamethasone, hydrocortisone, and prednisone; peptide APIs like teduglutide and bivalirudin; as well as fermentation-based products, cytotoxic APIs, and narcotic analgesics, offered under stringent quality controls compliant with international standards such as cGMP and EDQM. It also provides contract development and manufacturing organization (CDMO) services for pharmaceutical intermediates and APIs, targeting global pharmaceutical companies, biotech firms, and research institutions in the healthcare and life sciences sectors.
Founded in 2001 and headquartered in Taizhou, Zhejiang Province, China, the company operates primarily in China with international sales extending to Europe, North America, and Asia-Pacific regions through subsidiaries and export channels. Zhejiang Jiuzhou Pharmaceutical focuses on high-barrier, high-value products in the steroid hormone, peptide, and fermentation segments of the pharmaceutical industry, serving major multinational clients with customized synthesis and scale-up production capabilities.
In recent developments, the company expanded its production capacity through the completion of a new API facility in 2024, enhancing output for steroid and peptide products to meet growing global demand. It formed a strategic partnership with a leading European pharmaceutical firm in early 2025 for the co-development of novel peptide therapeutics, marking its entry into innovative drug modalities. Additionally, Zhejiang Jiuzhou secured a significant funding round from institutional investors in late 2024 to support R&D investments and international market expansion, alongside launching two new generic formulations for the Chinese market.